TLX090试验第1阶段开始 TLX090,这是用于治疗骨癌疼痛的新型放射药剂,预示着安全、持久解脱的早期希望。 Telix begins Phase 1 trial of TLX090, a new radiopharmaceutical for bone cancer pain, showing early promise for safe, long-lasting relief.

Telix药业已开始为SOLACE第一阶段试验中的患者提供TLX090 (153Samarium- DOTMP) 剂量,这是一种针对晚期癌症骨转移的新型放射性药物. Telix Pharmaceuticals has begun dosing patients in the SOLACE Phase 1 trial for TLX090 (153Samarium-DOTMP), a new radiopharmaceutical targeting pain from bone metastases in advanced cancer. 这次试验将招收33名病人来评估安全性、剂量和减轻疼痛。 The trial will enroll up to 33 patients to evaluate safety, dosing, and pain relief. TLX090旨在向骨头肿瘤提供定向辐射,同时保持健康组织,提供潜在的非类阿片系统治疗,单剂量可以减轻3至4个月的痛苦。 TLX090 aims to deliver targeted radiation to bone tumors while sparing healthy tissue, offering a potential non-opioid, systemic treatment with a single dose that may relieve pain for 3–4 months. 早期数据表明安全状况良好,效果良好。 Early data suggest a favorable safety profile and promising effectiveness. 药剂的冷基配方和药房配送可以改善药品的获取。 The drug’s cold-kit formulation and pharmacy-based distribution could improve access. 与休斯顿肿瘤顾问一起进行的试验可能支持简化监管途径。 The trial, conducted with Oncology Consultants in Houston, may support a streamlined regulatory path. TLX090仍在调查中,在任何地方都没有获得批准。 TLX090 remains investigational and has not been approved anywhere.